loader
report-image

SGLT-2 Inhibitor Market Size & Share - By Type (Canagliflozin, Dapagliflozin, Empagliflozin, Remogliflozin), By Application Segmentation (Type 2 diabetes management, Heart failure treatment, Chronic kidney disease management), By Distribution Channel Segmentation (Hospital pharmacies, Retail pharmacies, Online pharmacies) and By Region: Global & Forecast, 2024-2033

  • PUBLISHED ON
  • 2023-12-07
  • NO OF PAGES
  • 211
  • CATEGORY
  • Healthcare & Life Sciences

Market Overview

SGLT-2 Inhibitor Market Size is projected to achieve a value of USD 10.21 Billion in 2023, with a linear behavior in the market growth it is forecasted to achieve a value of USD 20.65 Billion by 2033 with a CAGR of 8.5% during the forecast period 2024-2033.

Type 2 diabetes is treated with a class of drugs called sodium-glucose co-transporter 2 (SGLT-2) inhibitors. By inhibiting the kidneys' SGLT-2 protein, they decrease the absorption of glucose and increase its excretion in urine. By lowering blood sugar levels, this process helps with diabetes management. SGLT-2 inhibitors have also been linked to cardiovascular benefits and may aid in weight loss. But occasionally, they can raise the risk of vaginal yeast infections and urinary tract infections.

            Get more in-depth information of this reports – Request Free Sample

The primary factor propelling the SGLT-2 inhibitor market is its effectiveness in the treatment of type 2 diabetes. Due to their special advantages, which include lowering cardiovascular risks and promoting weight loss, these drugs are gaining popularity among patients and medical professionals looking to treat diabetes patients completely. Further propelling market expansion are their ability to complement current treatment regimens and ease of oral administration. The growing demand for and use of SGLT-2 inhibitors in the pharmaceutical industry is partly due to the rising incidence of diabetes worldwide.

Market Scope

Report Attributes

Description

Market Size in 2023

USD 10.21 Billion

Market Forecast in 2033

USD 20.65 Billion

CAGR % 2023-2033

8.5%

Base Year

2023

Historic Data

2016-2022

Forecast Period

2024-2033

Report USP

 

Production, Consumption, company share, company heatmap, company production capacity, growth factors and more

Growth Drivers

The increasing prevalence of type 2 diabetes globally contributes to the growing demand for effective antidiabetic medications, including SGLT-2 inhibitors.

The inclusion of SGLT-2 inhibitors in treatment guidelines and recommendations by healthcare organizations has influenced prescribing patterns and increased their use in clinical practice.

SGLT-2 inhibitors have demonstrated renoprotective effects by slowing the progression of kidney disease in people with diabetes. This aspect has increased their appeal in treating diabetic nephropathy.

Segments Covered

by Type, by Application, by Distribution Channel and By Region

Regional Scope

North America, Europe, APAC, South America and Middle East and Africa

Country Scope

U.S.; Canada; U.K.; Germany; France; Italy; Spain; Benelux; Nordic Countries; Russia; China; India; Japan; South Korea; Australia; Indonesia; Thailand; Mexico; Brazil; Argentina; Saudi Arabia; UAE; Egypt; South Africa; Nigeria

 

SGLT-2 Inhibitor Industry:  Dynamics & Restrains

Market Drivers

Additional positive Cardiovascular Benefits - The SGLT-2 inhibitor Market inhibitors is mostly driven by the additional beneficial cardiovascular effects that are linked to these drugs. Research has demonstrated that these drugs are more than just glucose-lowering agents, with decreased risks of heart failure, cardiovascular events, and possible protective effects on the kidney. Healthcare practitioners looking for all-inclusive treatments for diabetic patients at risk of cardiovascular issues are drawn to this extended therapeutic profile, which has completely changed ideas about how patients should be treated. In addition to boosting market expansion and establishing SGLT-2 inhibitors as essential components in diabetes management with additional cardiovascular advantages, the promise of simultaneously addressing numerous health concerns raises the appeal and adoption rates of these drugs.

Effectiveness in Glycemic Control - The commercial expansion of SGLT-2 inhibitors is mostly driven by how well they manage blood sugar levels. By preventing the kidneys from reabsorbing glucose, these drugs provide a unique mechanism that lowers blood sugar. Healthcare professionals looking for strong glucose-lowering drugs are drawn to their effectiveness, which is frequently on par with or better than conventional diabetes therapies. Their usefulness is further increased by their capacity to supplement current treatments or offer a substitute for patients who are intolerant to other drugs. Because of its remarkable ability to control blood sugar levels, SGLT-2 inhibitors are fundamental to diabetes treatment plans, which greatly contributes to their market domination and ongoing success.

Market Restrains

Side Effects and Safety Concerns - The SGLT-2 inhibitor Market has been severely limited by side effects and safety concerns. Patients and healthcare professionals are being cautious due to adverse effects such as vaginal mycotic infections, urinary tract infections, and the possibility of diabetic ketoacidosis. These safety concerns restrict their use despite their effectiveness, particularly in specific patient groups or those with predisposing factors. Prescription patterns and patient acceptance are further impacted by regulatory monitoring and warnings, which makes patients more cautious while using SGLT-2 inhibitors. To relieve these constraints and guarantee broader market adoption, it is imperative to address these worries through improved education, more transparent risk communication, and ongoing research to reduce adverse consequences.

SGLT-2 Inhibitor Segmentation

Market- By Type Analysis

By Type, the SGLT-2 inhibitor Market is Categories into Canagliflozin, Dapagliflozin, Empagliflozin, Remogliflozin. The Canagliflozin segment accounts for the largest share of around 35% in 2022.


Canagliflozin introduced first reliable clinical evidence for its safety and effectiveness for the treatment of chronic renal disease, heart failure, and type 2 diabetes, broad label.

The following segments are part of an in-depth analysis of the global market for Parkinson's disease therapies:

Market Segments

 

by Application

·         Type 2 diabetes management

·         Heart failure treatment

·         Chronic kidney disease management

By Distribution Channel

·         Hospital pharmacies

·         Retail pharmacies

·         Online pharmacies

Would you like this research report to be customized to meet your needs?

The information needed to assist you in making wise business decisions

will be covered by our research team – Customize this report


SGLT-2 Inhibitor Market Industry: Regional Analysis

North America Market Forecast

North America dominate the SGLT-2 inhibitor Market with the highest revenue generating market with share of more than 47%. The SGLT-2 inhibitor market has expanded as a result of advantageous reimbursement policies, a big population of diabetics, and raised awareness, also AstraZeneca, Johnson & Johnson, and other businesses are well-represented in this market.



Europe Market Statistics

Europe is the second-largest market for SGLT-2 inhibitor. European nations have differing adoption rates. Some nations, like Germany, France, and the UK, have welcomed SGLT-2 inhibitors because of how well they work to treat diabetes. However, differences in pricing regulations and healthcare systems among European countries have resulted in differences in market penetration.

APAC Market Forecasts

Asia Pacific is expected to be the fastest-growing market for SGLT-2 inhibitor during the forecast period. SGLT-2 inhibitors are becoming more and more widespread in nations like South Korea, Japan, and Australia. Because of the country's high rate of diabetes and its healthcare providers' proactive adoption of innovative treatments, Japan has proven to be a particularly important market. Although the industry is expanding in other regions of Asia, variables including the state of the healthcare system and economic growth may have an impact.

Competitive Analysis

The SGLT-2 inhibitor Market is dominated by a few large companies, such as

·         AstraZeneca

·         Boehringer Ingelheim

·         Bristol-Myers Squibb

·         Daiichi Sankyo

·         Eli Lilly and Company

·         GlaxoSmithKline

·         Johnson & Johnson

·         Merck & Co.

·         Novo Nordisk

·         Sanofi

There are some of the key trends that are shaping the competitive landscape of the SGLT-2 inhibitor Market.

·         October 2023, AstraZeneca announced that Farxiga (dapagliflozin) has been approved by the European Medicines Agency (EMA) for the treatment of chronic kidney disease (CKD) in adults at risk of progression to end-stage kidney disease (ESKD) and cardiovascular events, regardless of their diabetes status.

·         February 2022, The USFDA approved Boehringer Ingelheim's use of Jardiance (empagliflozin) for additional purposes to reduce hospitalization and death risk in patients with heart failure and low ejection fraction, as well as in those with type 2 diabetes with prior cardiovascular illness.

1.      Global SGLT-2 inhibitor Market Introduction and Market Overview

1.1.   Objectives of the Study

1.2.   Global SGLT-2 inhibitor Market Scope and Market Estimation

1.2.1.      Global SGLT-2 inhibitor Overall Market Size, Revenue (US$ Mn), Market CAGR (%), Market forecast (2023 - 2033)

1.2.2.      Global SGLT-2 inhibitor Market Revenue Share (%) and Growth Rate (Y-o-Y) from 2019 - 2033

1.3.   Market Segmentation

1.3.1.      Component of Global SGLT-2 inhibitor Market

1.3.2.      Technology of Global SGLT-2 inhibitor Market

1.3.3.      Distribution Channel of Global SGLT-2 inhibitor Market

1.3.4.      Region of Global SGLT-2 inhibitor Market

2.      Executive Summary

2.1.   Global SGLT-2 inhibitor Market Industry Trends under COVID-19 Outbreak

2.1.1.      Global COVID-19 Status Overview

2.1.2.      Influence of COVID-19 Outbreak on Global SGLT-2 inhibitor Market Industry Development

2.2.   Market Dynamics

2.2.1.      Drivers

2.2.2.      Limitations

2.2.3.      Opportunities

2.2.4.      Impact Analysis of Drivers and Restraints

2.3.   Pricing Trends Analysis & Average Selling Prices (ASPs)

2.4.   Key Mergers & Acquisitions, Expansions, JVs, Funding / VCs, etc.

2.5.   Porter’s Five Forces Analysis

2.5.1.      Bargaining Power of Suppliers

2.5.2.      Bargaining Power of Buyers

2.5.3.      Threat of Substitutes

2.5.4.      Threat of New Entrants

2.5.5.      Competitive Rivalry

2.6.   Value Chain / Ecosystem Analysis

2.7.   Russia-Ukraine War Impacts Analysis

2.8.   Economic Downturn Analysis

2.9.     Market Investment Opportunity Analysis (Top Investment Pockets), By Segments & By Region

3.      Global SGLT-2 inhibitor Market Estimates & Historical Trend Analysis (2019 - 2022)

4.      Global SGLT-2 inhibitor Market Estimates & Forecast Trend Analysis, by TYPE

4.1.   Global SGLT-2 inhibitor Market Revenue (US$ Mn) Estimates and Forecasts, by TYPE, 2019 to 2033

4.1.1.      Canagliflozin

4.1.2.      Dapagliflozin

4.1.3.      Empagliflozin

4.1.4.      Remogliflozin

5.      Global SGLT-2 inhibitor Market Estimates & Forecast Trend Analysis, by Application

5.1.   Global SGLT-2 inhibitor Market Revenue (US$ Mn) Estimates and Forecasts, by Application, 2019 to 2033

5.1.1.      Type 2 diabetes management

5.1.2.      Heart failure treatment

5.1.3.      Chronic kidney disease management

6.      Global SGLT-2 inhibitor Market Estimates & Forecast Trend Analysis, by Distribution Channel

6.1.   Global SGLT-2 inhibitor Market Revenue (US$ Mn) Estimates and Forecasts, by Distribution Channel, 2019 to 2033

6.1.1.      Hospital pharmacies

6.1.2.      Retail pharmacies

6.1.3.      Online pharmacies

7.      Global SGLT-2 inhibitor Market Estimates & Forecast Trend Analysis, by Region

7.1.   Global SGLT-2 inhibitor Market Revenue (US$ Mn) Estimates and Forecasts, by Region, 2019 to 2033

7.1.1.      North America

7.1.2.      Europe

7.1.3.      Asia Pacific

7.1.4.      Middle East & Africa

7.1.5.      South America

8.      North America SGLT-2 inhibitor Market: Estimates & Forecast Trend Analysis

8.1.   North America SGLT-2 inhibitor Market Assessments & Key Findings

8.1.1.      North America SGLT-2 inhibitor Market Introduction

8.1.2.      North America SGLT-2 inhibitor Market Size Estimates and Forecast (US$ Million) (2019 – 2033)

8.1.2.1.  By TYPE

8.1.2.2.  By Application

8.1.2.3.  By Distribution Channel

8.1.2.4.  By Country

8.1.2.4.1.   The U.S.

8.1.2.4.2.   Canada

8.1.2.4.3.   Mexico

9.      Europe SGLT-2 inhibitor Market: Estimates & Forecast Trend Analysis

9.1.   Europe SGLT-2 inhibitor Market Assessments & Key Findings

9.1.1.      Europe SGLT-2 inhibitor Market Introduction

9.1.2.      Europe SGLT-2 inhibitor Market Size Estimates and Forecast (US$ Million) (2019 – 2033)

9.1.2.1.  By TYPE

9.1.2.2.  By Application

9.1.2.3.  By Distribution Channel

9.1.2.4.      By Country

9.1.2.4.1.   Germany

9.1.2.4.2.   U.K.

9.1.2.4.3.   France

9.1.2.4.4.   Italy

9.1.2.4.5.   Spain

9.1.2.4.6.   Russia

9.1.2.4.7.   Rest of Europe

10.  Asia Pacific SGLT-2 inhibitor Market: Estimates & Forecast Trend Analysis

10.1. Asia Pacific Market Assessments & Key Findings

10.1.1.  Asia Pacific SGLT-2 inhibitor Market Introduction

10.1.2.  Asia Pacific SGLT-2 inhibitor Market Size Estimates and Forecast (US$ Million) (2019 – 2033)

10.1.2.1.  By TYPE

10.1.2.2.  By Application

10.1.2.3.  By Distribution Channel

10.1.2.4.  By Country

10.1.2.4.1.              China

10.1.2.4.2.              Japan

10.1.2.4.3.              India

10.1.2.4.4.              Australia

10.1.2.4.5.              South Korea

10.1.2.4.6.              ASEAN

10.1.2.4.7.              Rest of Asia Pacific

11.  Middle East & Africa SGLT-2 inhibitor Market: Estimates & Forecast Trend Analysis

11.1. Middle East & Africa Market Assessments & Key Findings

11.1.1.  Middle East & Africa SGLT-2 inhibitor Market Introduction

11.1.2.  Middle East & Africa SGLT-2 inhibitor Market Size Estimates and Forecast (US$ Million) (2019 – 2033)

11.1.2.1.  By TYPE

11.1.2.2.  By Application

11.1.2.3.  By Distribution Channel

11.1.2.4.  By Country

11.1.2.4.1.                 U.A.E.

11.1.2.4.2.                 Saudi Arabia

11.1.2.4.3.                 Egypt

11.1.2.4.4.                 South Africa

11.1.2.4.5.                 Rest of Middle East & Africa

12.  South America SGLT-2 inhibitor Market: Estimates & Forecast Trend Analysis

12.1. South America Market Assessments & Key Findings

12.1.1.  South America SGLT-2 inhibitor Market Introduction

12.1.2.  South America SGLT-2 inhibitor Market Size Estimates and Forecast (US$ Million) (2019 – 2033)

12.1.2.1.  By TYPE

12.1.2.2.  By Application

12.1.2.3.  By Distribution Channel

12.1.2.4.  By Country

12.1.2.4.1.              Brazil

12.1.2.4.2.              Argentina

12.1.2.4.3.              Colombia

12.1.2.4.4.              Rest of South America

13.  Competition Landscape

13.1. Global SGLT-2 inhibitor Market Competition Matrix & Benchmarking, by Leading Players / Innovators / Emerging Players / New Entrants

13.2. Global SGLT-2 inhibitor Market Competition White Space Analysis, By Distribution Channel

13.3. Global SGLT-2 inhibitor Market Competition Heat Map Analysis, By Distribution Channel

13.4. Global SGLT-2 inhibitor Market Concentration & Company Market Shares (%) Analysis, 2022

14.  Company Profiles

14.1.                    AstraZeneca.

14.1.1.  Company Overview & Key Stats

14.1.2.  Financial Performance & KPIs

14.1.3.  Product Portfolio

14.1.4.  Business Strategy & Recent Developments

* Similar details would be provided for all the players mentioned below 

14.2.     Boehringer Ingelheim

14.3.     Bristol-Myers Squibb

14.4.     Daiichi Sankyo

14.5.     Eli Lilly and Company

14.6.     GlaxoSmithKline

14.7.     Johnson & Johnson

14.8.     Merck & Co.

14.9.     Novo Nordisk

14.10. Sanofi

15.  Research Methodology

15.1. External Transportations / Databases

15.2. Internal Proprietary Database

15.3. Primary Research

15.4. Secondary Research

15.5. Assumptions

15.6. Limitations

15.7. Report FAQs

16.  Research Findings & Conclusion

 

Quality Assurance Process

  1. We Market Research’s Quality Assurance program strives to deliver superior value to our clients.

We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.

Market Research Process




We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.

To mitigate risks that can impact project success, we deploy the follow project delivery best practices:
  • Project kickoff meeting with client
  • Conduct frequent client communications
  • Form project steering committee
  • Assign a senior SR executive as QA Executive
  • Conduct internal editorial & quality reviews of project deliverables
  • Certify project staff in SR methodologies & standards
  • Monitor client satisfaction
  • Monitor realized value post-project

Case Study- Automotive Sector

One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached We Market Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).

Solution

The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research

The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.

Market Estimates and Forecast

In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.

Case Study- ICT Sector

Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.


Business Solution

An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.


Conclusion

The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2033.

Frequently Asked Questions

What is the market size of SGLT-2 inhibitor Market in 2022?

SGLT-2 inhibitor Market was valued at USD 9.12 Billion in 2022.

What is the growth rate for the SGLT-2 inhibitor Market?

SGLT-2 inhibitor Market size will increase at approximate CAGR of 8.5% during the forecasted period.

Which are the top companies operating within the market?

Major companies operating within the SGLT-2 inhibitor Market are AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Novo Nordisk and Sanofi.

Which region dominates the SGLT-2 inhibitor Market?

North America dominates the market with an active share of 47%.

CHOOSE LICENSE TYPE
QLOUD
Pricing

Select a license type that suits your business needs

Single User Access

US $3950

Only Three Thousand Nine Hundred Fifty US dollar

  • 1 User access
  • 15% Additional Free Customization
  • Free Unlimited post-sale support
  • 100% Service Guarantee until achievement of ROI
Multi User Cost

US $4950

Only Four Thousand Nine Hundred Fifty US dollar

  • 5 Users access
  • 25% Additional Free Customization
  • Access Report summaries for Free
  • Guaranteed service
  • Dedicated Account Manager
  • Discount of 20% on next purchase
  • Get personalized market brief from Lead Author
  • Printing of Report permitted
  • Discount of 20% on next purchase
  • 100% Service Guarantee until achievement of ROI
Enterprise User Cost

US $5950

Only Five Thousand Nine Hundred Fifty US dollar

  • Unlimited User Access
  • 30% Additional Free Customization
  • Exclusive Previews to latest or upcoming reports
  • Discount of 30% on next purchase
  • 100% Service Guarantee until achievement of ROI